• Interaction Score: 3.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell line xenograft
    combination therapy CB-839 + Olaparib
    Evidence Type Actionable

    PMIDs:
    28346230


    Sources:
    JAX-CKB

  • Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27518686


    Sources:
    CIViC

  • Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type no benefit

    PMIDs:
    26802156


    Sources:
    JAX-CKB

  • Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16341243


    Sources:
    CIViC

  • Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration VHL:.
    Drug family [VEGFR inhibitor]
    combination therapy [Sorafenib,Sunitinib,Bevacizumab,Axitinib]


    Sources:
    JAX-CKB CGI

  • Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy [Sorafenib,Sunitinib,Bevacizumab,Axitinib]
    Drug family [VEGFR inhibitor]
    Alteration VHL:.


    Sources:
    JAX-CKB CGI

  • Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type renal cell carcinoma
    Response Type no benefit
    Approval Status Phase II

    PMIDs:
    26951309


    Sources:
    JAX-CKB

  • Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type renal cell carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26951309


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type renal cell carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    21170960


    Sources:
    JAX-CKB

  • Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration VHL:.
    Drug family [VEGFR inhibitor]
    combination therapy [Sorafenib,Sunitinib,Bevacizumab,Axitinib]

    PMIDs:
    None found


    Sources:
    CGI

  • Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type renal carcinoma
    Response Type decreased response
    Approval Status Preclinical

    PMIDs:
    21325073


    Sources:
    JAX-CKB

  • Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BPTES + Olaparib
    Indication/Tumor Type renal cell carcinoma
    Response Type sensitive

    PMIDs:
    28346230


    Sources:
    JAX-CKB

  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15217953


    Sources:
    NCI

  • Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Sunitinib + Trametinib
    Indication/Tumor Type kidney cancer
    Response Type predicted – sensitive

    PMIDs:
    26487278


    Sources:
    JAX-CKB

  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cediranib + Saracatinib
    Indication/Tumor Type renal clear cell carcinoma
    Response Type no benefit

    PMIDs:
    26802156


    Sources:
    JAX-CKB

  • Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14555188


    Sources:
    NCI

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy [Sorafenib,Sunitinib,Bevacizumab,Axitinib]
    Drug family [VEGFR inhibitor]
    Alteration VHL:.

    PMIDs:
    None found


    Sources:
    CGI